Novartis Ag

Schering Aktiengesellschaft

Other

Francesco Hofmann

Pascal Furet

Andreas Huth

Paul William Manley

Guido Bold

Dieter Seidelmann

Martin Haberey

Karl-Heinz Thierauch

Andreas Menrad

Karl-Heinz Altmann

Jeanette Marjorie Wood

Stefano Ferrari

Jürgen Mestan

Martin Krüger

Eric Billy

Frank Peter Stegmeier

William Raj Sellers

Martin Kr&uuml;ger

Tobias Schmelzle

Gregory Hoffman

Michael Ray Schlabach, Jr

Antoine De Weck

Javad Golji

Audrey Kauffmann

Konstantinos John Mavrakis

Earl Robert McDonald, Iii

J&uuml;rgen Mestan

The disclosure provides novel personalized therapies, kits, transmittable forms of information and methods for use in treating patients having cancer, wherein the cancer is amenable to therapeutic treatment with an inhibitor, e.g., an inhibitor of any of the targets disclosed herein. Kits, methods of screening for candidate inhibitors, and associated methods of treatment are also provided.

Compositions and methods to treat cancer

Described are compunds of formula (I), wherein W is O or S; X is NR; Y is CRR&#x2014;(CH)n wherein Rand Rare independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO; Ris aryl; Ris a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms with the exception that Rcannot represent 2-phthalimidyl, and in case of Y=SOcannot represent 2,1,3-benzothiadiazol-4-yl; any of R, R, Rand R, independently of the other, is H or a substituent other than hydrogen; and Rand R, independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.

N-Aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF

Described are compunds of formula (I), wherein W is O or S; X is NR; Y is CRR&#x2014;(CH)n wherein Rand Rare independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is SO; Ris aryl; Ris a bicyclic heteroaryl group comprising one ring nitrogen atom with the exception that Rcannot represent 2-phthalimidyl; any of R, R, Rand R, independently of the other, is H or a substituent other than hydrogen; and Rand R, independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.

VEGF receptor tyrosine kinase inhibitors

Described are compounds of formula (I), wherein W is O or S; X is NR ; Y is CR R &mdash;(CH )n wherein R and R are independently of each other hydrogen or lower alkyl, and n is an integer of from and including 0 to and including 3; or Y is S0 ; R is aryl; R is a mono- or bicyclic heteroaryl group comprising one or more ring nitrogen atoms with the exception that R cannot represent 2-phthalimidyl, and in case of Y&equals;SO cannot represent 2,1,3-benzothiadiazol-4-yl; any of R , R , R and R , independently of the other, is H or a substituent other than hydrogen; and R and R , independently of each other, are H or lower alkyl; or a N-oxide or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical product for the treatment of a neoplastic disease which responds to an inhibition of the VEGF receptor tyrosine kinase activity. The compounds of formula (I) can be used for the treatment e.g. of a neoplastic disease, such as a tumor disease, of retinopathy and age-related macular degeneration.

Growing community of inventors

Bottmingen, Switzerland

Francesco Hofmann